TirzepatideRanked
Find my match
Price index re-read 2026-10-15 NexLife prices 2026-11-06 Methodology v4.1 Programs priced 28 Corrections open log

Provider review

Shed tirzepatide review

What Shed charges, what is included, who prescribes, which pharmacy fills it, where it operates — and how much of that we confirmed ourselves rather than took from the website.

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.

Direct answer

We re-read Shed’s own pages on November 20, 2026. Its lowest all-in figure for compounded tirzepatide was $239 a month ('starting as low as'). Shed places =27 of 29 in our November 20, 2026 computed ranking, with 6 of the 40 points we measure for every program. Sections below that show July 2026 records are kept as dated history.

Answer last reviewed:
Methodology scorev4.1 · read the methodology
v4.1 re-score pending
Pricing transparency—/20
Total annual cost—/20
Clinical oversight—/15
Pharmacy transparency—/15
Support—/10
Regulatory disclosure—/10
Accessibility—/10
Not yet re-scored on methodology v4.1. Programs other than NexLife are listed alphabetically until they are.

What is distinctive about this programme

Breadth of formulation, at a cost

Shed publishes compounded semaglutide as injectable ($175 on twelve months), microdose ($149), sublingual lozenges ($199) and liquid drops ($229), plus tirzepatide injectable ($245) and microdose ($199), and liquid drops ($229). No other provider in our dataset offers that spread.

The sublingual and drops formats deserve the standard caution: no trial has tested a compounded sublingual or orally dissolving GLP-1, and bioavailability for these formulations is unpublished. They are priced comparably to injectables that do have trial evidence behind the molecule and route.

Pricing increases at higher doses

Shed is one of the few providers in our dataset explicitly reported as increasing price at higher doses. That matters more than the headline figure: a patient starting at $245 on a twelve-month tirzepatide plan should establish what 10 or 15 mg costs before committing, because the advertised rate is the entry rate.

The two-month minimum and the brand markup

Several programmes carry a two-month minimum, which is milder than a twelve-month prepayment but still removes the option of a single trial month.

Shed's brand offerings carry a $125 membership required for brand access. The Wegovy pen at $199 medication becomes $324 all-in, and Zepbound at $349 becomes $474 — against $299 to $449 direct from LillyDirect with no membership at all.

Shed — every captured offering, monthlyCaptured 2026-07-06
Semaglutide microdose$149Semaglutide injectable$175Tirzepatide microdose$199Semaglutide sublingual$199Semaglutide sublingual$229Tirzepatide injectable$245
Show this figure as a table
Data table
ItemValueEvidence
Semaglutide microdose$149Reported
Semaglutide injectable$175Reported
Tirzepatide microdose$199Reported
Semaglutide sublingual$199Reported
Semaglutide sublingual$229Reported
Tirzepatide injectable$245Reported
Formulations are not interchangeable. A microdose price is never compared against a standard injectable price, here or anywhere on this site.

Where it holds up

  • Widest formulation range in our dataset: injectable, microdose, sublingual and drops
  • Microdose semaglutide at $149 is competitively priced within its category
  • Two-month minimum is less restrictive than the twelve-month prepayments common elsewhere
  • Prices for sublingual formats have been reduced substantially from earlier listings

Where it does not

  • Pricing increases at higher doses — the advertised rate is the entry rate
  • Sublingual and drops formats have no trial evidence at all
  • Brand access requires a $125 membership on top of medication
  • Brand Zepbound at $474 all-in against $299–$449 direct from the manufacturer
  • Figures are third-party reported and not yet captured by us
How this provider prices, in one table
How this provider prices, in one table
FieldPosition
MembershipSeparate and required
Dose structureEscalates with dose or not established
Lowest captured figure$149/mo, prepaid term
Evidence statusThird-party reported, pending our own capture
Pharmacy named to usNo — provider-reported only
Every field moves to verified only when a named researcher captures it and archives the source.
How the 100 points are allocatedMethodology v4.1
Pricing transparency20 ptsTotal annual cost20 ptsClinical oversight15 ptsPharmacy transparency15 ptsSupport10 ptsRegulatory disclosure10 ptsAccessibility10 pts
Show this figure as a table
Methodology v4.1 weights
CategoryPoints
Pricing transparency20 pts
Total annual cost20 pts
Clinical oversight15 pts
Pharmacy transparency15 pts
Support10 pts
Regulatory disclosure10 pts
Accessibility10 pts
Seven weighted categories, 100 points. NexLife scores 94; other programs are listed alphabetically while their v4.1 re-scores are pending. Read the methodology

Pricing, all-in

Plan total and monthly equivalent are calculated by us from the provider's published figures, using the same formula applied to every provider on this site. A price is only a price once the required fees are inside it.

Shed — every captured pricing record
ProviderProgramFormulationDose coverageMedicationRequired feesAll-in monthlyPrice typeEvidenceCaptured
Shedprepaidcompounded injectable—$245—$245Commitment tierReported2026-07-06
Shedprepaidcompounded microdose—$199—$199Commitment tierReported2026-07-06
Shedprepaidcompounded microdose—$149—$149Commitment tierReported2026-07-06
Shedprepaidcompounded injectable—$175—$175Commitment tierReported2026-07-06
Shedmonth_to_monthcompounded sublingual—$199—$199RecurringReported2026-07-06
Shedprepaidcompounded sublingual—$229—$229Commitment tierReported2026-07-06

How this sits against the market

Lowest all-in monthly price, compounded tirzepatide, 33 programsPrice index, October 15, 2026; NexLife November 6, 2026
Collective$85.58WellMedr$89Mondae$114NexLife$115Embody$119NextMeds$119SnagRx$119yourEra$123NewMeMeds$125CoreAge Rx$129Eden Health$129SkinnyRx$129GobyMeds$133Telos RX$139Sprout Health$149Strut Health$149He & She MD$159Bodybuilding Health+$174.67bmiMD$179IVIM Health$192Alloy$199TelePep$214Yucca Health$225Found$239Pallas Health$239ShedRx$239MyDrHank$240Enhance.MD$280
Show this figure as a table
Lowest all-in monthly price by program, sorted low to high
ProgramAll-in monthlyRead
Collective$85.58Read 2026-10-15
WellMedr$89Read 2026-10-15
Mondae$114Read 2026-10-15
NexLife$115Read 2026-11-06
Embody$119Read 2026-10-15
NextMeds$119Read 2026-10-15
SnagRx$119Read 2026-10-15
yourEra$123Read 2026-10-15
NewMeMeds$125Older record, 2026-09-20
CoreAge Rx$129Read 2026-10-15
Eden Health$129Read 2026-10-15
SkinnyRx$129Older record, 2026-08-27
GobyMeds$133Read 2026-10-15
Telos RX$139Read 2026-10-15
Sprout Health$149Read 2026-10-15
Strut Health$149Read 2026-10-15
He & She MD$159Read 2026-10-15
Bodybuilding Health+$174.67Read 2026-10-15
bmiMD$179Older record, 2026-09-17
IVIM Health$192Read 2026-10-15
Alloy$199Read 2026-10-15
TelePep$214Read 2026-10-15
Yucca Health$225Older record, 2026-09-12
Found$239Read 2026-10-15
Pallas Health$239Read 2026-10-15
ShedRx$239Read 2026-10-15
MyDrHank$240Older record, 2026-09-17
Enhance.MD$280Read 2026-10-15
Lowest figure each program prints for standard compounded tirzepatide, with annual memberships spread over 12 months. Sorted by price, not by our ranking. Some figures are sale prices or need prepayment; see the price index.
What Shed charges, component by component
Medication—Membership—Shipping—Dose surcharge—Consultation—Labs—Structure only. No widths are proportional to anything, because nothing is captured.
Show this figure as a table
Data table
ComponentAmount
Medicationnot captured
Membershipnot captured
Shippingnot captured
Dose surchargenot captured
Consultationnot captured
Labsnot captured
All-in totalnot captured
A provider that advertises only the first segment is quoting a price you cannot actually pay.
Where a headline price usually stops short
Where a headline price usually stops short
Cost componentInside the advertised figure?Charged anyway?
Medicationyesyes
Membership or program feeno—
Shippingno—
Higher-dose surchargeno—
Initial consultationno—
Required laboratory workno—
Cancellation or restocking termsno—

A dash means no figure held. How we grade evidence.

The right-hand column fills in per provider as capture proceeds. Until then it reads unverified, which is the honest state.
Verified price historyPending
no verified captures yet

This chart stays empty until two or more dated captures exist. Historical values are never estimated or backfilled from a provider's current page.

Against the category median
All-in monthlyThis provider — not capturedCategory median — not capturedMembership feeThis provider — not capturedCategory median — not capturedRubric scoreThis provider — not capturedCategory median — not capturedThis providerCategory median
Show this figure as a table
Data table
ItemThis providerCategory median
All-in monthlynot capturednot captured
Membership feenot capturednot captured
Rubric scorenot capturednot captured
Medians publish once enough of the comparison set is captured to make a median mean something.

What is included, and what is not

Where it holds up

  • nothing verified yet

Where it does not

  • nothing verified yet

Where it operates

State availability is verified against the provider's own checkout or a support confirmation, state by state, with a capture date. A provider serving forty states is not nationwide, and we do not describe it that way.

State research coverage
Researched and verified — 0 (0%)Not yet researched — 51 (100%)51records
Show this figure as a table
Where it operates
StatusRecordsShare
Researched and verified00%
Not yet researched51100%
51 jurisdictions, each researched separately. A shared rule still needs its own source.

Clinical model

Pharmacy and fulfilment

Billing, cancellation and support

What changed

Verified changes to this provider's terms
no dated events recorded yet
Show this figure as a table
What changed
No events recorded.
Events appear here when something dated actually happens, not to refresh a timestamp.
  • no entriesNothing has changed yet because nothing has been published yet. Entries appear here when a verified figure, score or conclusion changes, never for a typo fix.

How this compares to the category

Once enough providers are scored, this section reports where Shed sits against the median for each rubric category, not against a hand-picked competitor.

What we have asked Shed, and what they have answered0 of 55 available points unlocked
What we have asked Shed, and what they have answered
QuestionWorthTheir answerStatus
Pharmacy traceability and quality disclosures15 pts—Not answered Pending
Clinical oversight and care continuity20 pts—Not answered Pending
State access and operational reliability10 pts—Not answered Pending
Cancellation, billing and support transparency10 pts—Not answered Pending

A dash means no figure held. How we grade evidence.

Blank cells are the answer we have, which is none. This provider can change any row by replying — see the disclosure register for the exact questions and what an answer changes.

Questions readers actually ask

Is Shed the cheapest option?

We will not answer that until the all-in figures are captured for the whole comparison set. A cheapest claim needs a defined comparison group, a stated program type and a capture date, or it is just an adjective.

Is this review sponsored?

No. Reviews here are not sponsored, and no provider can buy a score, a placement or a review. Tirzepatide Ranked is affiliate-supported; the disclosure page explains how.

Is compounded tirzepatide the same as Zepbound?

No. Compounded preparations are not FDA-approved products and there is no generic tirzepatide. Approval of the brand product does not extend to a compounded preparation.

Cite this pageCC BY 4.0

Tirzepatide Ranked. “Shed Tirzepatide Review.” S.J Partners LLC, 2026-07-26. https://tirzepatideranked.com/providers/shed/

Quote the capture date beside a figure, not the date you read this page. Why.

Report an error

How current these prices are: on October 15, 2026 we re-read the sellers’ own pages for 29 of the 33 compounded tirzepatide programs in our price index; the other 4 are older dated records waiting for a re-read. NexLife’s prices were re-read on November 6, 2026. Any older figure on this page keeps the date it was read.

Comparing 0 of 4